Under the deal, Tramorgan has secured the exclusive marketing sales and distribution rights of Innovus’ topical consumer care product to increase penile sensitivity. The deal has an initial
The company said that the trial failed to meet its primary endpoint of non-inferiority; however, the results showed that HbA1c was reduced for patients on either regimen, to
The once-weekly subcutaneous injection, Trulicity is designed to improve glycemic control (blood sugar levels), along with diet and exercise, in these patients. Trulicity is not recommended as first-line
The NIAID has exercised two additional options under its contract with BioCryst, which provides for GMP drug substance and drug product manufacture of BCX4430. So far, BioCryst has
The FDA orphan drug status is based upon an estimated 40,000 procedures being performed in patients with these cancers. Navidea Interim CEO Michael Goldberg said this Orphan Drug
As part of the €465m deal, Boehringer will start clinical investigation of CV9202 in at least two different lung cancer settings, in combination with afatinib in patients with
The two firms will jointly discover and develop multiple ADCs, antibodies linked to cytotoxic drugs for more targeted delivery, using Sutro’s cell-free protein synthesis platforms Xpress CF and
The Phase III trial is designed to assess the efficacy and safety of plazomicin compared to colistin in patients with bloodstream infections and nosocomial pneumonia caused by carbapenem-resistant
The deal will see Sanofi provide about $200m in equity investments, milestone payments and research and development services over the next four years. Sanofi has already paid MyoKardia
Tildrakizumab is a humanized, anti-IL-23p19 monoclonal antibody that binds specifically to IL-23p19 and is designed to selectively block the cytokine IL-23. It is currently being evaluated in Phase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.